Modality
Cell Therapy
MOA
SOS1i
Target
PI3Kα
Pathway
Apoptosis
ALLDLBCL
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
Jan 2019
→ Oct 2027
Phase 3Current
NCT08676684
430 pts·ALL
2019-01→2025-12·Recruiting
NCT08448414
941 pts·DLBCL
2024-08→2027-10·Not yet recruiting
1,371 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-263mo agoPh3 Readout· ALL
2027-10-151.5y awayPh3 Readout· DLBCL
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Recruit…
P3
Not yet…
Catalysts
Ph3 Readout
2025-12-26 · 3mo ago
ALL
Ph3 Readout
2027-10-15 · 1.5y away
DLBCL
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08676684 | Phase 3 | ALL | Recruiting | 430 | UPDRS |
| NCT08448414 | Phase 3 | DLBCL | Not yet recr... | 941 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |